Medicure Inc. · TSXV:MPH

Medicure — Investor Presentation (April 2024)

14 slides from Medicure's investor presentation, Apr 23, 2024

  1. Slide 1: Investor Presentation

    Medicure Inc. Investor Presentation 2024 SD-MED-AA-01

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-loo

  3. Slide 3: Medicure's 4 Focuses

    Medicure’s 4 Focuses Medicure is a profitable R&D specialty pharmaceutical company focused on the US market with an e-commerce pharmacy 1. Growing sales of ZYPITAMAG 2. Growing sales of Marley Drug E-Commerce pharmacy subsidiary 3. Maintain sales of AGGRASTAT 4. Launch and complete Phase 3 Trial of

  4. Slide 4: Medicure's Growth Strategy

    Medicure’s Growth Strategy Medicure plans to use its profit to fund R&D and acquisitions Short term: Near term: Long term: Growth of ZYPITAMAG, Build the Marley Drug Development of new Marley Drug and maintain business through acquisition pharma products for AGGRASTAT and partnerships significant un

  5. Slide 5: Why Did Medicure Acquire Marley Drug Pharmacy

    Why Did Medicure Acquire Marley Drug Pharmacy • A more efficient distribution and marketing vehicle for ZYPITAMAG – a branded drug • A marketing vehicle for other branded drugs • Saves on high fees to wholesalers and pharmacy benefit managers MPH:TSXV 5

  6. Slide 6: Key Financial Parameters

    Key Financial Parameters Net Revenue Adjusted EBITDA1 $25.0 $3.5 $3.0 $20.0 $2.5 $15.0 $CAD (M) $2.0 $1.5 $10.0 $1.0 $5.0 $0.5 $0.0 $0.0 2021 2022 2023 2021 2022 2023 1The Company defines EBITDA as "earnings before interest, taxes, depreciation, amortization and other income or expense" and Adjusted

  7. Slide 7: Key Financial Parameters

    Key Financial Parameters R&D Expenses Net Cash Increases $3.0 $1.6 $1.4 $2.5 $1.2 $2.0 $1.0 $CAD (M) $1.5 $0.8 $0.6 $1.0 $0.4 $0.5 $0.2 $0.0 $0.0 2021 2022 2023 2021 2022 2023 MPH:TSXV 7

  8. Slide 8: Key Financial Parameters

    Key Financial Parameters Net Income before Non-Cash Adjustments Net Income (Loss) after Non-Cash Adjustments $4.0 $3.0 $3.5 $2.0 $3.0 $1.0 $2.5 $CAD (M) $2.0 $0.0 $1.5 -$1.0 $1.0 -$2.0 $0.5 $0.0 -$3.0 2021 2022 2023 2021 2022 2023 MPH:TSXV 8

  9. Slide 9: Medicure's Leadership Team

    Medicure’s Leadership Team Haaris Uddin Reuben Saba Albert D. Friesen Neil Owens Vice President, Chief Financial Officer Chief Executive Officer & President & Business Development Chairman of the Board Chief Operating Officer • Founded Medicure in • President & COO since • Joined Medicure in 2022 •

  10. Slide 10: ZYPITAMAG

    $5.0M INDICATION In 2023 High Cholesterol PRODUCT HIGHLIGHTS • Improvements over older statins 73% • Low rates of side effects like muscle pain Sales through • Doesn’t interact with other medications Marley Drug • Once daily low dose with strong LDL reduction $ 4B Statin market MPH:TSXV 10

  11. Slide 11: Medicure's Pharmacy Subsidiary & E-Commerce Website

    Medicure’s Pharmacy Subsidiary & E-Commerce Website WHAT IS MARLEY DRUG $ 9.6M • A US pharmacy subsidiary licensed to ship FDA approved medications to all 50 states In 2023 • Facilitates Medicure selling ZYPITAMAG directly to consumers 23% HIGHLIGHTS from the prior year • More than 100,000 customers

  12. Slide 12: AGGRASTAT

    INDICATION Acute Coronary Syndrome $9.7M PRODUCT HIGHLIGHTS • Leading IV antiplatelet in its class In 2023 • Medicure grew market share from 2% to 65% • Used in more than 1,200 hospitals • Three formats of the product available MPH:TSXV 12

  13. Slide 13: Development of MC-1 for Rare Pediatric Disease

    PHASE 3 CLINICAL STUDY Development of MC-1 for Rare Pediatric Disease Phase 3 study for treatment of rare pediatric disease called PNPO deficiency • Study involves 10-15 patients in US and Australia • Orphan Drug Status and Fast Track Designation • Study is in Launch Phase • If approved Medicure is

  14. Slide 14: Thank You for Your Interest

    Thank You for Your Interest For Further Information Visit our Websites Investor Relations Medicure.com ir@medicure.com AGGRASTAT.com 1-888-435-2220 (Ext. 228) ZYPITAMAG.com Marley Drug.com Follow us on LinkedIn MPH:TSXV 14

Medicure — Investor Presentation (April 2024) on 6ix